| Bioactivity | RDEA 806 is an orally active non-nucleoside reverse transcriptase inhibitor (NNRTI) that exhibits potent in vitro inhibitory activity against both wild-type HIV-1 (EC50 of 3.05 nM) and NNRTI-resistant HIV-1[1]. |
| CAS | 878670-61-2 |
| Formula | C24H18BrClN4O3S |
| Molar Mass | 557.85 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Moyle G, et al. Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects[J]. Antimicrobial agents and chemotherapy, 2010, 54(8): 3170-3178. |
RDEA 806
CAS: 878670-61-2 F: C24H18BrClN4O3S W: 557.85
RDEA 806 is an orally active non-nucleoside reverse transcriptase inhibitor (NNRTI) that exhibits potent in vitro inhibi
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.